Glycopyrrolate ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
34	Neurofibromatosis	1

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02382198 (ClinicalTrials.gov)	July 2016	21/1/2015	Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease	A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease	Sialorrhea;Parkinson's Disease	Drug: Glycopyrrolate;Drug: Placebo	Ottawa Hospital Research Institute	NULL	Unknown status	30 Years	N/A	All	28	Phase 2	Canada

34. Neurofibromatosis

---

Clinical trials : 133 /  Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03513757 (ClinicalTrials.gov)	March 4, 2018	4/2/2018	Dexmedetomidine and Propofol for Pediatric MRI Sedation	An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging	Headache;Tumor;Seizure Disorder;Neurofibromatoses;Hydrocephalus;Abdominal Neoplasm;Spine Deformity	Drug: propofol;Drug: Dexmedetomidine;Drug: Glycopyrrolate;Drug: Lidocaine 1% Injectable Solution;Drug: Nitrous Oxide;Drug: Sevoflurane	Medical College of Wisconsin	NULL	Completed	12 Months	60 Months	All	40	Phase 4	United States